Frontier AI firm Profluent has entered a multi-program strategic research collaboration with Eli Lilly and Co. LLY to develop and commercialize custom site-specific recombinases to treat genetic ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Cancer isn't a static target. Its genetic profile can change. So even with the newer targeted therapies, a patient's care ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S.

Eli Lilly and Co (NYSE:LLY) has agreed to acquire private clinical-stage biotechnology firm Kelonia Therapeutics in a deal ...

In recent years, the U.S. Food and Drug Administration has approved more than a dozen gene-editing and cell-based therapies. We are now in the second great wave of the genetic revolution, not defined ...

This photo provided by Emily’s Entourage in April 2025 shows Emily Kramer-Golinkoff, who has cystic fibrosis caused by a rare genetic mutation, during a trip to Maine. (Emily’s Entourage via AP) Emily ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first ...

Emily Kramer-Golinkoff can’t get enough oxygen with each breath. Advanced cystic fibrosis makes even simple things like walking or showering arduous and exhausting. She has the most common fatal ...